“To me, the biggest differentiator might be how the patient wants to experience care,” said Krish Patel, MD, on treatment options for patients with lymphoma.
|Articles|August 1, 1995
Oncology NEWS International
- Oncology NEWS International Vol 4 No 8
- Volume 4
- Issue 8
Medarex, Ciba Form Partnership
ANNANDALE, NJ--Medarex, Inc. and Ciba-Geigy, Ltd. have entered into an alliance for developing and marketing Medarex's MDX-210 Bispecific product. Medarex will be primarily responsible for development through phase II trials, and Ciba will be responsible for phase III trials, regulatory approvals, and commercial launch.
Advertisement
ANNANDALE, NJ--Medarex, Inc. and Ciba-Geigy, Ltd. have enteredinto an alliance for developing and marketing Medarex's MDX-210Bispecific product. Medarex will be primarily responsible fordevelopment through phase II trials, and Ciba will be responsiblefor phase III trials, regulatory approvals, and commercial launch.
MDX-210 is designed to induce tumor cell killing by simultaneouslybinding to the HER-2 protein on the cancer cell surface and toa key receptor on immune system killer cells. The product is currentlyin clinical trials for the treatment of breast, ovarian, prostate,and other tumors.
Articles in this issue
about 31 years ago
CA 125 Predicts Response to Chemo in Ovarian Caabout 31 years ago
Biochemical Modulation Promising in RT-Resistant GI Cancerabout 31 years ago
Cancer Institute of NJ Adds to its Staffabout 31 years ago
A Century of Breast Cancer Litigation Is 'Deconstructed'about 31 years ago
New Depot Formulation of LHRH Analogue Allows 12-Week Dosingabout 31 years ago
NSABP Investigation Threatens Academic Freedom for All: Fisherabout 31 years ago
Cancer Fax Directory in 3rd Editionabout 31 years ago
HIV-Related Malignancies Increasing, Physicians Tell Panelabout 31 years ago
Breast Cancer Risk Factors Remain Elusive TargetAdvertisement
Related to this article
Ayal Aizer, MD, MHS, says Alliance A071801 supports fractionated SRS as standard after resection, with comparable radiation necrosis rates.
Jyoti Malhotra, MD, MPH on first-in-human clinical trials, lung cancer precision medicine in 2026, the disparities tension in drug development, and her move to Yale Cancer Center.
A personalized ctDNA assay demonstrated 100% specificity but limited sensitivity for detecting recurrence after liver transplantation in HCC and CCA.
The FDA cleared the SpaceOAR Flex System, a hydrogel spacer used during prostate cancer radiotherapy, in a 510(k) supported by the HYDROSPACE trial.
Phase 2 ASPEN-06 data showed higher response rates with evorpacept added to trastuzumab, ramucirumab, and paclitaxel in HER2-positive gastric cancer.
In 62 patients with ICI-naive HPV16-Positive HNSCC, 17.7% experienced grade 3 or 4 treatment-related adverse events.
Ethan B. Ludmir, MD, details which cholangiocarcinoma subsets, by tumor location, may benefit most from neoadjuvant radiation before surgery.
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Radiation May Improve Tolerability in Cholangiocarcinoma
2
Distal Extrahepatic Cholangiocarcinoma May Gain From Neoadjuvant Radiation
3
Isatuximab-Based Therapy Shows “Impressive” PFS Projections in NDMM
4
Subcutaneous Isatuximab Enhances Patient Experience in Multiple Myeloma
5